Explore

Trendline Trendline
Corbus Pharmaceuticals Appoints Nishant Saxena as Chief Business Officer Amidst Key Clinical Developments

Corbus Pharmaceuticals Appoints Nishant Saxena as Chief Business Officer Amidst Key Clinical Developments

Corbus Pharmaceuticals Appoints Nishant Saxena as Chief Business Officer Amidst Key Clinical Developments
Trendline Trendline
Corbus Pharmaceuticals Appoints Nishant Saxena as Chief Business Officer and Plans ASCO Conference Call

Corbus Pharmaceuticals Appoints Nishant Saxena as Chief Business Officer and Plans ASCO Conference Call

Corbus Pharmaceuticals Appoints Nishant Saxena as Chief Business Officer and Plans ASCO Conference Call
Trendline Trendline
Eisai Presents New Clinical Evidence for Lenvatinib at ASCO 2026

Eisai Presents New Clinical Evidence for Lenvatinib at ASCO 2026

Eisai Presents New Clinical Evidence for Lenvatinib at ASCO 2026
Trendline Trendline
Longeveron Outlines Strategic Repositioning and Key Milestones for 2026

Longeveron Outlines Strategic Repositioning and Key Milestones for 2026

Longeveron Outlines Strategic Repositioning and Key Milestones for 2026
Trendline Trendline
Bristol Myers Squibb to Present New Oncology Data at ASCO 2026 Highlighting Innovative Cancer Treatments

Bristol Myers Squibb to Present New Oncology Data at ASCO 2026 Highlighting Innovative Cancer Treatments

Bristol Myers Squibb to Present New Oncology Data at ASCO 2026 Highlighting Innovative Cancer Treatments
Trendline Trendline
FDA Veteran Paz Vellanki Joins Precision for Medicine, Enhancing Regulatory Expertise

FDA Veteran Paz Vellanki Joins Precision for Medicine, Enhancing Regulatory Expertise

FDA Veteran Paz Vellanki Joins Precision for Medicine, Enhancing Regulatory Expertise
Trendline Trendline
858 Therapeutics Reports Promising Results from Phase 1/2 Trial of PARG Inhibitor ETX-19477 in Cancer Treatment

858 Therapeutics Reports Promising Results from Phase 1/2 Trial of PARG Inhibitor ETX-19477 in Cancer Treatment

858 Therapeutics Reports Promising Results from Phase 1/2 Trial of PARG Inhibitor ETX-19477 in Cancer Treatment
Trendline Trendline
Accent Therapeutics to Present Clinical Study on ATX-295 at ASCO Meeting, Targeting Chromosomal Instability in Cancer

Accent Therapeutics to Present Clinical Study on ATX-295 at ASCO Meeting, Targeting Chromosomal Instability in Cancer

Accent Therapeutics to Present Clinical Study on ATX-295 at ASCO Meeting, Targeting Chromosomal Instability in Cancer
Trendline Trendline
SystImmune to Present New Clinical Data on Izalontamab Brengitecan at ASCO 2026

SystImmune to Present New Clinical Data on Izalontamab Brengitecan at ASCO 2026

SystImmune to Present New Clinical Data on Izalontamab Brengitecan at ASCO 2026
Trendline Trendline
Lantern Pharma Receives FDA Approval for HARMONIC Phase 2 Trial Amendments

Lantern Pharma Receives FDA Approval for HARMONIC Phase 2 Trial Amendments

Lantern Pharma Receives FDA Approval for HARMONIC Phase 2 Trial Amendments
Trendline Trendline
ATB Therapeutics Appoints Mark Throsby as CEO to Lead Growth Phase

ATB Therapeutics Appoints Mark Throsby as CEO to Lead Growth Phase

ATB Therapeutics Appoints Mark Throsby as CEO to Lead Growth Phase
Trendline Trendline
ATB Therapeutics Appoints Mark Throsby as CEO to Lead Next Phase of Growth

ATB Therapeutics Appoints Mark Throsby as CEO to Lead Next Phase of Growth

ATB Therapeutics Appoints Mark Throsby as CEO to Lead Next Phase of Growth